
KalVista Pharmaceuticals launches with GBP8m in Series A funding
KalVista Pharmaceuticals (KalVista), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences. The company is developing novel, small molecule plasma kallikrein inhibitors, which represent a new approach




